<DOC>
	<DOCNO>NCT00056173</DOCNO>
	<brief_summary>This phase II , 43 patient trial , evaluate efficacy GTI-2040 , antisense oligonucleotide complementary R2 component ribonucleotide reductase ( RNR ) mRNA , combination capecitabine , set advanced/metastatic renal cell carcinoma . Preclinical study show synergy GTI-2040 capecitabine renal cell carcinoma .</brief_summary>
	<brief_title>Combination Capecitabine GTI-2040 Treatment Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Age great equal 18 . Histologically cytologically confirm diagnosis advance metastatic renal cell carcinoma effective therapy available unresponsive conventional therapy . Measurable disease . To consider measurable , lesion must accurately measure least one dimension ( long diameter record ) great equal 20 mm conventional technique great equal 10 mm spiral CT scan . Karnofsky performance status great equal 70 . Be able central venous like access maintain throughout study . Provide write informed consent prior initiation protocol therapy . Appropriate organ function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
</DOC>